CTLA4 and metastatic malignant neoplasm: When combined with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, it enabled approximately 84% of treated tumor-bearing mice to achieve long-term survival and 34% to develop tumor-specific immunity, offering a promising approach for metastatic cancer treatment 345.